Compugen Stock Price, News & Analysis

Compugen (Nasdaq: CGEN) has announced that new clinical data will be presented at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in Houston, Texas, from November 8-10, 2024. The presentation will focus on the anti-tumor activity and safety of a triple combination therapy involving COM701, COM902, and pembrolizumab in heavily pre-treated patients with platinum-resistant ovarian cancer.

The poster presentation, titled "Triple blockade of DNAM-1axis with COM701 (anti-PVRIG) + COM902 (anti-TIGIT) + pembrolizumab shows preliminary antitumor activity in patients with platinum resistant ovarian cancer, interim results of Phase I trial," will be delivered by Dr. Oladapo Yeku, a Medical Oncologist from Massachusetts General Hospital, on Friday, November 8, 2024. The abstract number for this presentation is 985.

Compugen (Nasdaq: CGEN) will present at the Single Cell Genomics 2024 conference in Greece from September 16-18, 2024. Dr. Roy Granit, Head of Computational Discovery, will showcase a poster on applying AI to gain insights into the novel immune checkpoint PVRIG through single-cell and spatial transcriptomics.

The presentation highlights additional biological insights generated using Compugen's AI/ML-powered computational discovery platform, UnigenTM. These findings support the potential of PVRIG inhibition to induce anti-tumor activity in indications previously resistant to immunotherapy, differentiating it from other immune checkpoints.

The poster presentation, titled 'Applying AI to Gain Insights into the Novel Immune Checkpoint PVRIG Through Single-Cell and Spatial Transcriptomics,' is scheduled for Monday, September 16, 2024. It will be available on Compugen's website following the presentation.

Compugen (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company, announced its upcoming virtual presentation at the H.C. Wainwright 26th Annual Global Investment Conference. The presentation will be available on-demand starting September 9, 2024, at 7:00 AM ET for 30 days on the company's Investor Relations website.

Compugen, known for its pioneering work in computational target discovery, aims to showcase its latest developments and strategies to investors and industry professionals. This presentation offers an opportunity for stakeholders to gain insights into Compugen's progress in the competitive field of cancer immunotherapy.

Compugen (CGEN) reported Q2 2024 results, highlighting key achievements and financial updates:

1. FDA clearance of COM503 IND triggered a $30 million milestone payment from Gilead.

2. On track to present data from COM701 + COM902 + pembrolizumab study in platinum-resistant ovarian cancer in Q4 2024.

3. AstraZeneca provided a non-risk adjusted peak year revenue target of over $5 billion for rilvegostomig, with Compugen eligible for future milestones and royalties.

4. Q2 2024 revenues: $6.7 million, compared to no revenues in Q2 2023.

5. Cash position: $92.3 million as of June 30, 2024, with runway expected to fund operations into 2027.

6. Net loss: $2.1 million ($0.02 per share) in Q2 2024, compared to $9.3 million ($0.11 per share) in Q2 2023.

Compugen (Nasdaq: CGEN) has received FDA clearance for its investigational new drug (IND) application for COM503, a potential first-in-class, high-affinity anti-IL-18 binding protein antibody for the treatment of solid tumors. This clearance triggers a $30 million milestone payment from Gilead Sciences, Inc., Compugen's licensing partner. The company is on track to initiate a Phase 1 trial for COM503 in Q4 2024.

COM503 represents a differentiated antibody approach to harness cytokine biology for cancer therapeutics, both as monotherapy and in combination treatments. This achievement strengthens Compugen's balance sheet, extending its expected cash runway into 2027. The company's preparation for the Phase 1 trial is well-advanced, showcasing its execution capabilities and diverse pipeline developed through its computational discovery engine.

Compugen (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and pioneer in computational target discovery, has announced the upcoming release of its second quarter 2024 financial results. The results will be disclosed on Tuesday, August 6, 2024, before the U.S. financial markets open. Following the release, the company's management will host a conference call and webcast at 8:30 AM ET to review the results and provide a corporate update.

Investors and interested parties can access the live conference call by dialing 1-866-744-5399 from the U.S. or +972-3-918-0644 internationally. Additionally, a live webcast will be available through Compugen's website. For those unable to attend the live event, a replay will be made available on the company's website following the webcast.

Compugen (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company, announced that its SVP of Preclinical Development and Corporate Operations, Pierre Ferré, Ph.D, will present at the 12th Antibody Industrial Symposium in Montpellier, France, on June 21, 2024. The presentation will focus on a case study regarding clinical dose selection for TIGIT monospecific and bispecific antibodies. This event is an important platform for discussing advancements in antibody research and development.

Compugen has announced that it will receive a $5 million milestone payment from AstraZeneca following the dosing of the first patient in the Phase 3 TROPION-Lung10 trial. This trial evaluates the efficacy and safety of rilvegostomig, a PD-1/TIGIT bispecific antibody, as monotherapy and in combination with datopotamab deruxtecan for first-line treatment of non-squamous non-small cell lung cancer patients with high PD-L1 expression. The trial is expected to enroll approximately 675 patients across 14 countries. This milestone is part of Compugen's strategy to expand its pipeline through partnerships, following a previous $10 million payment related to the ARTEMIDE-Biliary01 Phase 3 trial.

Compugen (Nasdaq: CGEN) reported its Q1 2024 financials, highlighting key clinical advancements and financials. The company completed enrollment for its COM701 + COM902 + pembrolizumab study in platinum-resistant ovarian cancer, with data expected in Q4 2024. Data from its study on MSS CRC with liver metastases will be presented at ASCO 2024. Plans to file an IND for COM503 in H2 2024 are on track. Compugen's partner, AstraZeneca, advanced rilvegostomig to a second Phase 3 trial in NSCLC.

Financially, Compugen had $101.3 million in cash as of Mar 31, 2024, up from $51.1 million at the end of 2023, bolstered by payments from Gilead and AstraZeneca. The company reported $2.6 million in revenue for Q1 2024 and reduced net loss to $7.3 million, compared to $9.3 million in Q1 2023. R&D and G&A expenses also saw a decline. The cash runway is expected to fund operations into 2027.